Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Page 1
Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
Baumrin E, Shin DB, Mitra N, Pidala J, El Jurdi N, Lee SJ, Loren AW, Gelfand JM. Baumrin E, et al. Among authors: pidala j. JAMA Dermatol. 2024 Apr 1;160(4):393-401. doi: 10.1001/jamadermatol.2023.6277. JAMA Dermatol. 2024. PMID: 38416506
CONCLUSIONS AND RELEVANCE: The results of this cohort study demonstrated that skin chronic GVHD was independently associated with long-term PRO impairment, with sclerotic and combination disease carrying the highest morbidity. ...
CONCLUSIONS AND RELEVANCE: The results of this cohort study demonstrated that skin chronic GVHD was independently associated with long-te …
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR. Lee CJ, et al. Among authors: pidala ja. Transplant Cell Ther. 2022 Oct;28(10):712.e1-712.e8. doi: 10.1016/j.jtct.2022.07.014. Epub 2022 Jul 18. Transplant Cell Ther. 2022. PMID: 35863740 Free PMC article.
Chronic graft-versus-host disease (cGVHD) occurs in up to 25% of children following allogeneic hematopoietic cell transplantation (HCT) and continues to be a major cause of late morbidity and poor quality of life among long-term survivors of pediatric HCT. Late effects (LE …
Chronic graft-versus-host disease (cGVHD) occurs in up to 25% of children following allogeneic hematopoietic cell transplantation (HCT) and …
Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease.
Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, Cutler C, Hamilton BK, Lee SJ, Arora M. Chen GL, et al. Among authors: pidala j. Haematologica. 2023 Feb 1;108(2):483-489. doi: 10.3324/haematol.2021.279814. Haematologica. 2023. PMID: 35615925 Free PMC article.
Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST). Durable discontinuation of ST reflects the resolution of active chronic GvHD. ...
Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST). Durable discontinuat …
A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial.
Yang MJ, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, Gore LR, Khera N, Lau P, Sauls RM, Jones SR, Vinci C. Yang MJ, et al. Among authors: pidala j. PLoS One. 2022 Apr 1;17(4):e0266316. doi: 10.1371/journal.pone.0266316. eCollection 2022. PLoS One. 2022. PMID: 35363799 Free PMC article.
TRIAL REGISTRATION: The current study is registered in clinicaltrials.gov (NCT05078229); see https://clinicaltrials.gov/ct2/show/NCT05078229?term=christine+vinci&draw=2&rank=1....
TRIAL REGISTRATION: The current study is registered in clinicaltrials.gov (NCT05078229); see https://clinicaltrials.gov/ct2/show/NCT05078229 …
Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Al Malki MM, Badawy SM, Beitinjaneh A, Ganguly S, Hamilton B, Hildebrandt GC, Lekakis LJ, Liu H, Maziarz RT, Modi D, Murthy HS, Preussler JM, Sharma A, Spellman SR, Arora M, Lee SJ. Bhatt VR, et al. Among authors: pidala ja. Transplant Cell Ther. 2022 Jan;28(1):34-42. doi: 10.1016/j.jtct.2021.10.002. Epub 2021 Oct 9. Transplant Cell Ther. 2022. PMID: 34637965 Free PMC article.
The effect of chronic graft-versus-host disease (cGVHD) on the risk of nonrelapse mortality (NRM) and relapse has not been specifically studied in older adults, who are increasingly undergoing allogeneic hematopoietic cell transplantation (alloHCT) and surviving long-term …
The effect of chronic graft-versus-host disease (cGVHD) on the risk of nonrelapse mortality (NRM) and relapse has not been specifically stud …
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.
Wolff D, Radojcic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, Cheng GS, Sheshadri A, Bergeron A, Williams KM, Todd JL, Teshima T, Cuvelier GDE, Holler E, McCurdy SR, Jenq RR, Hanash AM, Jacobsohn D, Santomasso BD, Jain S, Ogawa Y, Steven P, Luo ZK, Dietrich-Ntoukas T, Saban D, Bilic E, Penack O, Griffith LM, Cowden M, Martin PJ, Greinix HT, Sarantopoulos S, Socie G, Blazar BR, Pidala J, Kitko CL, Couriel DR, Cutler C, Schultz KR, Pavletic SZ, Lee SJ, Paczesny S. Wolff D, et al. Among authors: pidala j. Transplant Cell Ther. 2021 Oct;27(10):817-835. doi: 10.1016/j.jtct.2021.06.001. Epub 2021 Jun 10. Transplant Cell Ther. 2021. PMID: 34217703 Free PMC article.
The working group made the following recommendations: (1) Phenotype chronic GVHD clinically and biologically in future cohorts, to describe the incidence, prognostic factors, mechanisms of organ damage, and clinical evolution of highly morbid conditions including long-term …
The working group made the following recommendations: (1) Phenotype chronic GVHD clinically and biologically in future cohorts, to describe …
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Pidala J, et al. Blood. 2020 Jan 9;135(2):97-107. doi: 10.1182/blood.2019003125. Blood. 2020. PMID: 31738834 Free PMC article. Clinical Trial.
In addition, sirolimus therapy spares steroid exposure and allied toxicity, does not compromise long-term survival outcomes, and is associated with improved patient-reported quality of life. ...
In addition, sirolimus therapy spares steroid exposure and allied toxicity, does not compromise long-term survival outcomes, and is a …
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.
Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B. Pidala J, et al. JAMA Oncol. 2020 Jan 1;6(1):e192974. doi: 10.1001/jamaoncol.2019.2974. Epub 2020 Jan 9. JAMA Oncol. 2020. PMID: 31556923 Free PMC article.
OBJECTIVES: To examine factors associated with successful immune suppression discontinuation and risk for immune suppression discontinuation failure under conventional HCT approaches and develop a practical tool to estimate successful immune suppression discontinuation likelihood …
OBJECTIVES: To examine factors associated with successful immune suppression discontinuation and risk for immune suppression discontinuation …
The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index.
Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ. Pidala JA, et al. Biol Blood Marrow Transplant. 2019 Dec;25(12):2468-2473. doi: 10.1016/j.bbmt.2019.07.040. Epub 2019 Aug 5. Biol Blood Marrow Transplant. 2019. PMID: 31394265 Free PMC article. Clinical Trial.
A composite endpoint called "failure-free survival" (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignancy, and death, has been suggested as a possible long-term indicator of success. The goal of the current study was to identify changes …
A composite endpoint called "failure-free survival" (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignan …
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.
Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ. Khera N, et al. Among authors: pidala ja. Biol Blood Marrow Transplant. 2019 Mar;25(3):599-605. doi: 10.1016/j.bbmt.2018.09.040. Epub 2018 Oct 5. Biol Blood Marrow Transplant. 2019. PMID: 30296479 Free PMC article.
Future research should investigate potential interventions to provide optimal and affordable care to at-risk patients and prevent long-term adverse financial outcomes in this vulnerable group....
Future research should investigate potential interventions to provide optimal and affordable care to at-risk patients and prevent long-te …
22 results